TMS Co., Ltd.

4891

JP3544960002

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-15 am EDT			5-day change	1st Jan Change
242 ^JPY	-0.41%		-6.56%	+28.72%

May. 14	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	MT
May. 03	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	MT

TMS Co., Ltd. announced that it has received ¥684.324069 million in funding

January 30, 2024

On January 31, 2024, TMS Co., Ltd. closed the transaction.

Latest news about TMS Co., Ltd.

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	May. 14	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	May. 03	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	May. 01	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Jefferies Adjusts TMS’ Price Target to 760 Yen From 730 Yen, Keeps at Buy	Apr. 15	MT
Tennant Minerals Raises AU$4.8 Million for Drilling, Target Testing; Shares Down 4%	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
Tennant Minerals Finds 23% Copper Concentrate, 1.5G/T Gold at Bluebird Project	Mar. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise	Mar. 25	MT
Tennant Minerals to Commence Next Phase of Drilling at Barkly Project; Shares Down 3%	Mar. 10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat	Mar. 01	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Feb. 29	MT
TMS Co., Ltd. Submits Clinical Trial Plan Notification for TMS-008 Phase I Clinical Trial in Japan	Feb. 29	CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading	Feb. 27	MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading	Feb. 26	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 23	MT
Greenbrook TMS Shares Tumble Ahead of Delisting; Trading to be Suspended Monday	Feb. 23	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Feb. 21	MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Wednesday Trading	Feb. 14	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Feb. 13	MT
Tennant Minerals Extends High-Grade Copper-Gold Zone at Northern Territory's Bluebird Discovery; Shares Jump 14%	Feb. 12	MT

TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Sector

Biotechnology & Medical Research

Calendar

2024-07-11 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

243 JPY

Average target price

760 JPY

Spread / Average Target

+212.76%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TMS CO., LTD.	+28.72%	62.61M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+43.45%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research

TMS Co., Ltd.

Equities

4891

JP3544960002

Biotechnology & Medical Research

TMS Co., Ltd. announced that it has received ¥684.324069 million in funding

Latest news about TMS Co., Ltd.

Chart TMS Co., Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research